These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging. Reimer P; Weissleder R; Lee AS; Buettner S; Wittenberg J; Brady TJ Radiology; 1991 Mar; 178(3):769-74. PubMed ID: 1994416 [TBL] [Abstract][Full Text] [Related]
4. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver. Tanimoto A; Kuribayashi S Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158 [TBL] [Abstract][Full Text] [Related]
5. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats. Leveille-Webster CR; Rogers J; Arias IM Hepatology; 1996 Jun; 23(6):1631-41. PubMed ID: 8675187 [TBL] [Abstract][Full Text] [Related]
6. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Weissleder R; Elizondo G; Wittenberg J; Lee AS; Josephson L; Brady TJ Radiology; 1990 May; 175(2):494-8. PubMed ID: 2326475 [TBL] [Abstract][Full Text] [Related]
7. Use of magnetite particles as a contrast agent for MR imaging of the liver. Kawamura Y; Endo K; Watanabe Y; Saga T; Nakai T; Hikita H; Kagawa K; Konishi J Radiology; 1990 Feb; 174(2):357-60. PubMed ID: 2296645 [TBL] [Abstract][Full Text] [Related]
8. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. Weissleder R; Reimer P; Lee AS; Wittenberg J; Brady TJ AJR Am J Roentgenol; 1990 Dec; 155(6):1161-7. PubMed ID: 2122660 [TBL] [Abstract][Full Text] [Related]
9. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718 [TBL] [Abstract][Full Text] [Related]
10. Superparamagnetic iron oxide enhanced magnetic resonance imaging of rat liver with hepatocellular carcinoma and benign hyperplastic nodule. Ishida T; Murakami T; Kato N; Takahashi M; Miyazawa T; Tsuda K; Tomoda K; Narumi Y; Nakamura H Invest Radiol; 1997 May; 32(5):282-7. PubMed ID: 9140748 [TBL] [Abstract][Full Text] [Related]
11. A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent. Josephson L; Groman EV; Menz E; Lewis JM; Bengele H Magn Reson Imaging; 1990; 8(5):637-46. PubMed ID: 1707120 [TBL] [Abstract][Full Text] [Related]
12. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents. Reimer P; Kwong KK; Weisskoff R; Cohen MS; Brady TJ; Weissleder R J Magn Reson Imaging; 1992; 2(2):177-81. PubMed ID: 1562768 [TBL] [Abstract][Full Text] [Related]
13. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents. Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202 [TBL] [Abstract][Full Text] [Related]
14. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. Senéterre E; Weissleder R; Jaramillo D; Reimer P; Lee AS; Brady TJ; Wittenberg J Radiology; 1991 May; 179(2):529-33. PubMed ID: 2014305 [TBL] [Abstract][Full Text] [Related]
15. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222 [TBL] [Abstract][Full Text] [Related]